免疫细胞素Hu14.18-IL-2对黑色素瘤病人的免疫激活作用  

Immune Activation of Immunocytokine Hu14.18-IL-2 in Patients with Melanoma

作　　者：宋继萍 Jacquelyn A.Hank Paul M.Sondel 

机构地区：[1]北京天坛生物制品股份有限公司,北京100024 [2]美国威斯康星大学癌症综合研究中心

出　　处：《中国生物制品学杂志》2007年第9期681-684,687,共5页Chinese Journal of Biologicals

摘　　要：目的评估免疫细胞素Hu14.18-IL-2对黑色素瘤病人体内免疫作用。方法33位黑色素瘤病人用一种人源化抗神经节苷脂GD-2的单抗与IL-2融合的免疫细胞素进行治疗,按每天0.8、1.6、3.2、4.8、6.0、7.5 mg/m2静脉滴注,连续3 d为一疗程,病情稳定或缓解后,在第5周接受第2疗程治疗。观察病人外周血单核淋巴细胞抗体依赖的细胞毒性、自然杀伤细胞活性、IL-2的体外增殖以及IL-2可溶性受体的变化。结果Hu14.18-IL-2能诱导病人淋巴细胞的吞噬作用,增强外周血中自然杀伤细胞的杀伤能力和数目,使血清中IL-2受体复合体的可溶性受体α链水平上升。结论免疫细胞素Hu14.18-IL-2对黑色素瘤病人具有免疫激活作用。Objective To evaluate the in vivo immune activation of immunocytokine Hul4. 18-IL-2 in the patients with melanoma. Methods Thirty-three patients were treated with Hul4. 18-IL-2,a humanized anti-GD-2 McAb linked to IL-2,by intravenous drip for 3 d as the 1 st course at dosages of 0. 8,1.6,3.2,4. 8,6. 0 and 7. 5 mg/m2 respectively. The patients received the 2nd course of treatment at the 5 th week after stabilization or remission of disease. The peripheral blood mononuclear cell （PBMC） antibody-dependent cytotoxicity, NK cell activity as well as in vitro proliferation and soluble receptor of IL-2 of patients before and after treatment were observed. Results Hul4. 18-IL-2 induced the phagocytosis of lymphocytes,enhanced the killing activity of NK cells in peripheral blood and increased the level of soluble alpha chain of IL-2 receptor complex in sera. Conclusion Hul4. 18-IL-2 showed immune activation in patients with melanoma.

关 键 词：免疫细胞素 黑色素瘤 免疫激活 

分 类 号：R392-33[医药卫生—免疫学] R735[医药卫生—基础医学]